Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

CureVac, NL0015436031

CureVac, NL0015436031

26.05.2021 - 13:03:21

CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates

Bettina J?dicke-Braas, Manager Communications CureVac, T?bingen, Germany T: +49 7071 9883-1087bettina.joedicke-braas@curevac.com

CureVac Investor Relations Contact Dr. Sarah Fakih, Vice President Investor Relations CureVac, T?bingen, Germany T: +49 7071 9883-1298 M: +49 160 90 496949sarah.fakih@curevac.com

Forward-Looking Statements CureVac This press release contains statements that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac AG, CureVac Real Estate GmbH, CureVac Inc. and CureVac Swiss AG (the "company") regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would," "could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

Cash and Condensed Consolidated Profit and Loss Data

?

? ? ? ? ? (in ? millions) ? December 31, 2020 ? March 31, 2021 ? ? ? ? ? (unaudited) ? Cash and Cash Equivalents ? 1,322.6 ? 1,496.9 ? ? ? ? ? ? ? ? ? ? ? ? ? ? Three months ended March 31, ? (in ? millions) ? 2020 ? 2021 ? ? ? (unaudited) ? (unaudited) ? Revenue ? 3.1 ? 10.0 ? Cost of Sales, Operating Expenses & Other Operating Income ? -26.3 ? -125.8 ? Operating Result ? -23.2 ? -115.8 ? Financial Result ? -0.7 ? 3.6 ? Pre-Tax Loss ? -23.9 ? -112.2 ?

26.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: CureVac Friedrich-Miescher-Str. 15 72076 T?bingen

Germany EQS News ID: 1200854 ? End of News DGAP News Service

1200854??26.05.2021?

@ dgap.de